Clinical Trial Update: A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A [Phase 3]

View source ↗

Summary

Phase 3 study evaluating NT-501 for Macular Telangiectasia Type 2 has completed enrollment with results posted in 2024, reporting data on safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Telangiectasia Type

Drugs mentioned

• NT-501

Snippet

Sponsor: Neurotech Pharmaceuticals | Conditions: Macular Telangiectasia Type 2 (MacTel) | Phase 3 | Status: COMPLETED | Results posted: 2024-09-24